| Autor: |
Aguiar-Bujanda D; Department of Medical Oncology, Hospital Universitario de Gran Canaria Dr Negrin, C/Barranco de la Ballena s/n, 35010, Las Palmas de Gran Canaria, Spain., Blanco-Sánchez MJ, Jiménez-Gallego P, Mori-De Santiago M, Hernández-Sosa M, Galván-Ruíz S, Hernández-Sarmiento S, Saura-Grau S, Bohn-Sarmiento U |
| Jazyk: |
angličtina |
| Zdroj: |
Future oncology (London, England) [Future Oncol] 2014 Oct; Vol. 10 (12), pp. 1967-80. |
| DOI: |
10.2217/fon.14.104 |
| Abstrakt: |
The prognosis of follicular lymphoma (FL) has significantly improved over the last decade, particularly following the introduction of the anti-CD20 monoclonal antibody rituximab, which has challenged the old concept of FL as an incurable disease. However, the decision whether to start treatment in a patient with advanced FL or adopt a watch-and-wait policy remains a subject of controversy. Furthermore, the optimal first-line treatment for FL remains a clinical challenge owing to the numerous different therapeutic options available. In this review, the authors focus on the initial management of patients with newly diagnosed FL, consider the different treatment options for every stage, paying special consideration to the therapeutic approaches for each clinical scenario, and discuss future directions. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
